WO2022229350A3 - Single-stranded oligonucleotides for use in the medical treatment and/or prophylaxis of virus infections - Google Patents
Single-stranded oligonucleotides for use in the medical treatment and/or prophylaxis of virus infections Download PDFInfo
- Publication number
- WO2022229350A3 WO2022229350A3 PCT/EP2022/061404 EP2022061404W WO2022229350A3 WO 2022229350 A3 WO2022229350 A3 WO 2022229350A3 EP 2022061404 W EP2022061404 W EP 2022061404W WO 2022229350 A3 WO2022229350 A3 WO 2022229350A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- virus
- prophylaxis
- stranded oligonucleotides
- medical treatment
- ssons
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title abstract 2
- 238000011321 prophylaxis Methods 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 230000009385 viral infection Effects 0.000 title abstract 2
- 241000714177 Murine leukemia virus Species 0.000 abstract 2
- 241000711975 Vesicular stomatitis virus Species 0.000 abstract 2
- 241001115402 Ebolavirus Species 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 1
- 241000712902 Lassa mammarenavirus Species 0.000 abstract 1
- 241000711828 Lyssavirus Species 0.000 abstract 1
- 241000712079 Measles morbillivirus Species 0.000 abstract 1
- 241000711798 Rabies lyssavirus Species 0.000 abstract 1
- 241000700584 Simplexvirus Species 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present disclosure relates to non-CpG single-stranded oligonucleotides (ssONs) with broad-spectrum antiviral activity for use in the treatment and/or prophylaxis of viral infections, such as Herpes simplex virus, Ebola virus, Lassa virus, Lyssa virus, rabies virus, measles virus, vesicular stomatitis virus (VSV), murine leukemia virus (MLV) and HIV-1, as well as multi-resistant HIV-1 infections, in a subject. Said ssONs have a length of at least 25 nucleotides and are stabilized by phosphorothioate internucleotide linkages and/or 2'-O-Methyl modifications.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE2150558 | 2021-04-30 | ||
| SE2150558-1 | 2021-04-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2022229350A2 WO2022229350A2 (en) | 2022-11-03 |
| WO2022229350A3 true WO2022229350A3 (en) | 2022-12-08 |
Family
ID=81877847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2022/061404 WO2022229350A2 (en) | 2021-04-30 | 2022-04-28 | Single-stranded oligonucleotides for use in the medical treatment and/or prophylaxis of virus infections |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2022229350A2 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016202779A1 (en) * | 2015-06-15 | 2016-12-22 | Spetz Holmgren Anna-Lena | Single-stranded oligonucleotides for use in the medical treatment of skin disorders |
| WO2019048555A1 (en) * | 2017-09-06 | 2019-03-14 | Jaerver Peter | Single stranded oligonucleotides inhibiting endocytosis |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5523389A (en) | 1992-09-29 | 1996-06-04 | Isis Pharmaceuticals, Inc. | Inhibitors of human immunodeficiency virus |
| KR101360955B1 (en) | 2002-09-13 | 2014-02-10 | 레플리코르 인코포레이티드 | non-sequence complementary antiviral oligonucleotides |
| WO2004076621A2 (en) | 2003-02-27 | 2004-09-10 | Yeda Research And Development Co. Ltd. | Compositions of nucleic acids for treating and detecting influenza virus |
| EP1802643A1 (en) | 2004-10-19 | 2007-07-04 | Replicor Inc. | Antiviral oligonucleotides |
| AR091065A1 (en) | 2012-05-18 | 2014-12-30 | Replicor Inc | A PHARMACEUTICAL FORMULATION THAT INCLUDES AN ANTIVIRAL OLIGONUCLEOTIDE CHELATE FOR THE TREATMENT OF AN ANTI-VIRAL INFECTION |
-
2022
- 2022-04-28 WO PCT/EP2022/061404 patent/WO2022229350A2/en active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016202779A1 (en) * | 2015-06-15 | 2016-12-22 | Spetz Holmgren Anna-Lena | Single-stranded oligonucleotides for use in the medical treatment of skin disorders |
| WO2019048555A1 (en) * | 2017-09-06 | 2019-03-14 | Jaerver Peter | Single stranded oligonucleotides inhibiting endocytosis |
Non-Patent Citations (5)
| Title |
|---|
| ANDREW VAILLANT ET AL: "Phosphorothioate Oligonucleotides Inhibit Human Immunodeficiency Virus Type 1 Fusion by Blocking gp41 Core Formation", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 50, no. 4, 1 April 2006 (2006-04-01), US, pages 1393 - 1401, XP055705135, ISSN: 0066-4804, DOI: 10.1128/AAC.50.4.1393-1401.2006 * |
| CARDIN RHONDA D ET AL: "Amphipathic DNA polymers exhibit antiviral activity against systemic Murine Cytomegalovirus infection", VIROLOGY JOURNAL, BIOMED CENTRAL, LONDON, GB, vol. 6, no. 1, 2 December 2009 (2009-12-02), pages 214, XP021069018, ISSN: 1743-422X * |
| CARSTEN SCHELLER ET AL: "Dual Activity of Phosphorothioate CpG Oligodeoxynucleotides on HIV", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, NEW YORK ACADEMY OF SCIENCES, US, vol. 1091, no. 1, 26 January 2007 (2007-01-26), pages 540 - 547, XP071403659, ISSN: 0077-8923, DOI: 10.1196/ANNALS.1378.095 * |
| D. I. BERNSTEIN ET AL: "Amphipathic DNA Polymers Exhibit Antiherpetic Activity In Vitro and In Vivo", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 52, no. 8, 1 August 2008 (2008-08-01), US, pages 2727 - 2733, XP055641550, ISSN: 0066-4804, DOI: 10.1128/AAC.00279-08 * |
| NOWROOZALIZADEH SALMA ET AL: "Suppression of HIV replication in vitro by CpG and CpG conjugated to the non toxic B subunit of cholera toxin", CURRENT HIV RESEARCH,, vol. 6, no. 3, 30 April 2008 (2008-04-30), pages 230 - 238, XP009538194, ISSN: 1873-4251, DOI: 10.2174/157016208784325038 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022229350A2 (en) | 2022-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MD20220043A2 (en) | Highly active compounds against COVID-19 | |
| MXPA05002791A (en) | Non-sequence complementary antiviral oligonucleotides. | |
| MY144616A (en) | Substituted dihydroquinazolines | |
| JP2008283975A5 (en) | ||
| WO2006121464A3 (en) | Compositions for treating respiratory viral infections and their use | |
| WO2005085268A3 (en) | Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | |
| WO2002096935A3 (en) | Long lasting fusion peptide inhibitors for hiv infection | |
| RU2014106765A (en) | VITAMIN B6 DERIVATIVES OF NUCLEOTIDES, Acyclic Nucleotides and Acyclic Nucleotide Phosphates | |
| WO2007042899B1 (en) | Human microrna targets in hiv genome and a method of identification thereof | |
| EA200701406A1 (en) | ACCESSIBLE FOR THE TREATMENT OF HIV COMPOUNDS | |
| WO2010068708A3 (en) | 3'-azido purine nucleotide prodrugs for treatment of viral infections | |
| WO2011130557A3 (en) | Phosphonates with reduced toxicity for treatment of viral infections | |
| JP2014500230A5 (en) | ||
| WO2021173713A8 (en) | Highly active compounds against covid-19 | |
| Lin et al. | Inhibitory effects of acyclic nucleoside phosphonate analogs, including (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine, on Epstein-Barr virus replication | |
| WO2022229350A3 (en) | Single-stranded oligonucleotides for use in the medical treatment and/or prophylaxis of virus infections | |
| WO2003101394A3 (en) | Defensins: use as antiviral agents | |
| PL1765370T3 (en) | Parapoxviruses in combination with other antiviral agents for the treatment of hiv/aids | |
| RU2014121304A (en) | INHIBITION OF EXPRESSION OF VIRAL GENES | |
| WO2008109352A4 (en) | Nucleic acid compounds for inhibiting akt gene expression and uses thereof | |
| WO2005023270A3 (en) | Compositions and methods for use of antiviral drugs in the treatment of retroviral diseases resistant to nucleoside reverse transcriptase inhibitors | |
| MX2020008061A (en) | Cycloalkyl substituted pyrazolopyrimidines having activity against rsv. | |
| CA2285463A1 (en) | A combination therapy for hiv infections | |
| MX2023005625A (en) | Pyrazolo derivatives as human dihydroorotate dehydrogenase (hdhodh) inhibitors for use as antivirals. | |
| WO2021226019A3 (en) | Compositions and methods for treating viral infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22727011 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 22727011 Country of ref document: EP Kind code of ref document: A2 |